S&P 500 Hits Record High as AI Rally Lifts Wall Street 
Paramount Skydance Completes $110 Billion Warner Bros Discovery Deal 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Iran Tanker Attacks Surge as Hormuz Oil Flows Near Prewar Levels 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Nasdaq Hits Record High as Tech Stocks Lift Wall Street 
Samsung, SK Hynix Shares Fall Ahead of Q3 Earnings 
Gate Launches Gate Money as Crypto Super App Race Heats Up 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
U.S. Issues Cuba Health Alert as Illnesses Rise 
Robinhood Buys $25 Million in Bitcoin for Corporate Treasury 
Indian Stocks Fall as RBI Hikes Rates to 5.50% 
Asian Currencies Mixed as Yen Weakens, Dollar Holds Firm 
Add as a preferred source on Google
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
